Movement Disorders

The Cleveland Clinic researcher details a study that will use biomarkers to develop a predictive model to identify individuals with Parkinson disease who may develop dementia.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

The director of Laryngology Research at Mass Eye and Ear spoke to the use of machine learning programs to aid physicians in the diagnosis of dystonia.

The upcoming phase 2b/3 study of mesdopetam in patients with Parkinson disease is set after the results of previous successful phase 1, phase 2a, and phase 2 studies.

The 5-year grant will support a research project that will use biomarkers to develop a predictive mathematical model to identify specific individuals with Parkinson disease who may develop dementia.

Patients treated with Axovant’s gene therapy AXO-Lenti-PD reported improvements of 40% in UPDRS-III scores, and 71% improvement in activities of daily living.

The postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.

The director of Laryngology Research at Mass Eye and Ear discussed how the AI-based DystoniaNet came to be and what challenges impact the diagnosis of dystonia.

Advanced imaging shows Parkinson disease can begin as brain-first or body-first.

Here's what is coming soon to NeurologyLive.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center provided insight on the lapses in levodopa-carbidopa treatment and what potential changes could come in the future.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center shared the reasons why LCIG is underused in clinical care.